One platform, from start to finish.
Onboard your participants
Total Consent Management incorporates easy-to-use tools like TeleVisit, remote scheduling, and compliant wet and dry signature to get your study started quickly and smoothly.
Take control of your trial
Keep your study on track and generate high-quality evidence with robust features like remote data collection, study notifications, participant reminders, and real-time reporting.
Data reporting and visualization
Oversight of your study data at your fingertips.
The Medable Effect
ROI for Phase III trials*
Rated DCT platform
Top Pharma customers
What makes us different
Best-in-class user experience
Informed by DCT experts, patient insights, and site feedback, the Medable platform accommodates the complex research landscape in an intuitive and simple user interface.
Designed to scale
Offered in over 60 countries and 120 languages, our cloud-agnostic, single API platform offers self-service build and a library of system integrations for maximum reach and scalability.
Extensive DCT network
Your study benefits from our extensive network of partners from retail pharmacy and site networks, data providers for RWE and LTFU, and direct-to-patient offering of connected sensors and home health providers.
The latest from Medable
The Definitive Guide to Digital Evidence Generation
According to Grandview Research, the hybrid and decentralized clinical trial (DCT) market will be worth more than 12 billion dollars by 2030. Sparked by the COVID-19 pandemic of 2020, the rapid ascent of patient-centered technology and the digital and decentralized trials they’ve spawned has forever changed the landscape of clinical conduct. Sponsors are increasingly turning to DCT platforms in alignment with the rise of Life Science and Software-as-a-Service (SaaS) solutions. For those who haven't made the jump yet, there are many questions, including "What is a decentralized clinical trial?" Find out with this in-depth guide to decentralized clinical trials. Uncover how they work, their benefits, and how they transform clinical development.
Medable Ranks in Top 8% of 2023 Inc. 5000 List of America’s Fastest-Growing Private Companies
Medable, the leading technology provider for patient-centric clinical trials, today announced that it ranked in the top 8 percent (#398) and was one of the top 50 software companies on the 2023 Inc. 5000, its annual list of the fastest-growing private companies in America. Medable’s ranking was fueled by its strong three-year growth rate of 1,453% from 2019 through 2022.
MRCT Center and Medable Launch First, Comprehensive IRB/EC Review Toolkit for Decentralized Clinical Trials
MRCT Center and Medable launch first-of-its-kind toolkit to provide a common framework, tools, and best practices for uniform ethical review and approval to simplify, streamline, and speed the IRB/EC process – a key step towards more efficient, patient-centered research execution.